DMII

Company Overview — What Does Drugs Made In America Acquisition II Corp. Do?

Drugs Made In America Acquisition II Corp. is a blank check company newly incorporated in the Cayman Islands as an exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses, which we refer to throughout this prospectus as our “initial business combination.” To date, our efforts have been limited to organizational activities as well as activities related to this offering. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business, industry or geographical location, we intend to focus our search for businesses in the pharmaceutical industry. We have assembled a strong management team with a broad network of connections and corporate relationships across the pharmaceutical industry. We are confident that we will be able to use our individual experiences as well as our networks to achieve success. Together, we will formulate an all-encompassing plan for growth, one that accounts for both organic expansion and expansion via mergers and acquisitions. In the end, we will attempt to transform our target company into a widely respected industry leader by leveraging the benefits of becoming a public company, including access to finance and equity for expansion. At the same time, we will endeavor to generate excellent returns for our shareholders. Our executive offices are located in Fort Lauderdale, FL. Drugs Made In America Acquisition II Corp. (DMII) is classified as a small-cap stock in the Financials sector, specifically within the Trading industry. The company is led by CEO Lynn Stockwell and employs approximately 2 people, headquartered in FORT LAUDERDALE, Florida. With a market capitalization of $655M, DMII is one of the notable companies in the Financials sector.

Drugs Made In America Acquisition II Corp. (DMII) Stock Rating — Reduce (April 2026)

As of April 2026, Drugs Made In America Acquisition II Corp. receives a Reduce rating with a composite score of 36.3/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.DMII ranks #2,111 out of 4,446 stocks in our coverage universe. Within the Financials sector, Drugs Made In America Acquisition II Corp. ranks #589 of 891 stocks, placing it in the lower half of its Financials peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

DMII Stock Price and 52-Week Range

Drugs Made In America Acquisition II Corp. (DMII) currently trades at $9.99. The 52-week high for DMII is $10.01, which means the stock is currently trading -0.2% from its annual peak. The 52-week low is $9.86, putting the stock 1.3% above its annual trough. Recent trading volume was 3K shares, suggesting relatively thin trading activity.

Is DMII Overvalued or Undervalued? — Valuation Analysis

Drugs Made In America Acquisition II Corp. (DMII) carries a value factor score of 37/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.35x, versus the sector average of 1.22x.

At current multiples, Drugs Made In America Acquisition II Corp. trades at a premium to most Financials peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Drugs Made In America Acquisition II Corp. Profitability — ROE, Margins, and Quality Score

Drugs Made In America Acquisition II Corp. (DMII) earns a quality factor score of 20/100, signaling below-average profitability metrics relative to the broader market. Return on assets (ROA) comes in at -0.0% versus the sector average of 1.2%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

DMII Debt, Balance Sheet, and Financial Health

Drugs Made In America Acquisition II Corp. has a debt-to-equity ratio of 0.0%, compared to the Financials sector average of 121.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. Total debt on the balance sheet is $0. Cash and equivalents stand at $315,087.

DMII has a beta of -0.01, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Drugs Made In America Acquisition II Corp. is 98/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.

Drugs Made In America Acquisition II Corp. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Drugs Made In America Acquisition II Corp. reported revenue of $0 and earnings per share (EPS) of $0.00. Net income for the quarter was $-46,158. Operating income came in at $-155,513.

In Q3 2025, Drugs Made In America Acquisition II Corp. reported revenue of $0 and earnings per share (EPS) of $0.00. Net income for the quarter was $-46,158. Operating income came in at $-155,513.

DMII Dividend Yield and Income Analysis

Drugs Made In America Acquisition II Corp. (DMII) does not currently pay a dividend. This is common among smaller companies in the Trading industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Financials dividend stocks may want to explore other Financials stocks or use the stock screener to filter by dividend yield.

DMII Momentum and Technical Analysis Profile

Drugs Made In America Acquisition II Corp. (DMII) has a momentum factor score of 31/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 48/100 reflects moderate short selling activity.

DMII vs Competitors — Financials Sector Ranking and Peer Comparison

Within the Financials sector, Drugs Made In America Acquisition II Corp. (DMII) ranks #589 out of 891 stocks based on the Blank Capital composite score. This places DMII in the lower half of all Financials stocks in our coverage universe. Key competitors and sector peers include WHITE MOUNTAINS INSURANCE GROUP LTD (WTM) with a score of 62.9/100, OPPENHEIMER HOLDINGS INC (OPY) with a score of 62.6/100, Enact Holdings, Inc. (ACT) with a score of 61.6/100, International General Insurance Holdings Ltd. (IGIC) with a score of 61.3/100, and PARKE BANCORP, INC. (PKBK) with a score of 60.4/100.

Comparing DMII against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full DMII vs S&P 500 (SPY) comparison to assess how Drugs Made In America Acquisition II Corp. stacks up against the broader market across all factor dimensions.

DMII Next Earnings Date

No upcoming earnings date has been announced for Drugs Made In America Acquisition II Corp. (DMII) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy DMII? — Investment Thesis Summary

The quantitative profile for Drugs Made In America Acquisition II Corp. suggests caution. The quality score of 20/100 flags below-average profitability. The value score of 37/100 indicates premium valuation. Momentum is weak at 31/100, a headwind for near-term performance. Low volatility (stability score 98/100) reduces downside risk.

In summary, Drugs Made In America Acquisition II Corp. (DMII) earns a Reduce rating with a composite score of 36.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on DMII stock.

Related Resources for DMII Investors

Explore more research and tools: DMII vs S&P 500 comparison, top Financials stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare DMII head-to-head with peers: DMII vs WTM, DMII vs OPY, DMII vs ACT.